Radiopharm Theranostics

NASDAQ: RADX ↗$1.66 USD~$22M (September 2026) MCAP

#Radiopharmaceuticals and Theranostics #Oncology #Brain Metastases Imaging #Pancreatic Ductal Adenocarcinoma #HER2-Positive Breast Cancer #Non-Small Cell Lung Cancer #Prostate Cancer #Glioblastoma

Radiopharm Theranostics is a clinical-stage radiopharmaceutical company developing paired diagnostic imaging and therapeutic candidates across several validated oncology targets, spanning peptides, small molecules and monoclonal antibodies radiolabelled with medical isotopes. Its pipeline pairs imaging agents such as 18F-RAD101 for recurrent brain metastases and Ga-68-RAD301 for pancreatic ductal adenocarcinoma with therapeutic assets including 177Lu-RAD202 in HER2-positive solid tumours and the B7-H3-targeted 177Lu-Betabart (RV-01) developed through a joint venture with MD Anderson Cancer Center. The company, which trades on both the ASX and Nasdaq, has a strategic agreement with Lantheus Holdings and isotope supply arrangements covering Lutetium-177 and Terbium-161.

Company Info

Sector:Radiopharmaceuticals / Theranostics

Headquarters:Carlton South, Victoria, Australia

Founded:2021

Website:radiopharmtheranostics.com/

Upcoming Milestones & Key Dates

October 1, 2026

Regulatory

FDA meeting to align on the global pivotal Phase 3 trial protocol for 18F-RAD101 in brain metastases

No recent news updates available for this company.

Leadership Team

Riccardo Canevari

Chief Executive Officer and Director

Paul Edward-Alexander Hopper

Founder and Executive Chairman

Dr. Dimitris Voliotis, M.D.

Chief Medical Officer

Aaron Laurita

Chief Financial Officer

Careers & Job Openings

No active job listings. Check back later.